| Therapeutic ligands antagonize estrogen receptor function by impairing its mobility J Guan, W Zhou, M Hafner, RA Blake, C Chalouni, IP Chen, T De Bruyn, ... Cell 178 (4), 949-963. e18, 2019 | 183 | 2019 |
| Structure-based identification of OATP1B1/3 inhibitors T De Bruyn, GJP Van Westen, AP IJzerman, B Stieger, P de Witte, ... Molecular pharmacology 83 (6), 1257-1267, 2013 | 143 | 2013 |
| Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity T De Bruyn, S Chatterjee, S Fattah, J Keemink, J Nicolaï, P Augustijns, ... Expert opinion on drug metabolism & toxicology 9 (5), 589-616, 2013 | 136 | 2013 |
| Disruption of IRE1α through its kinase domain attenuates multiple myeloma JM Harnoss, A Le Thomas, A Shemorry, SA Marsters, DA Lawrence, M Lu, ... Proceedings of the National Academy of Sciences 116 (33), 16420-16429, 2019 | 102 | 2019 |
| Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3 T De Bruyn, S Fattah, B Stieger, P Augustijns, P Annaert Journal of pharmaceutical sciences 100 (11), 5018-5030, 2011 | 93 | 2011 |
| Determination of OATP-, NTCP-and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes T De Bruyn, ZW Ye, A Peeters, J Sahi, M Baes, PF Augustijns, PP Annaert European journal of pharmaceutical sciences 43 (4), 297-307, 2011 | 67 | 2011 |
| Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer YC Chen, J Yu, C Metcalfe, T De Bruyn, T Gelzleichter, V Malhi, ... Expert Opinion on Investigational Drugs 31 (6), 515-529, 2022 | 61 | 2022 |
| Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine N Holmstock, T De Bruyn, J Bevernage, P Annaert, R Mols, J Tack, ... European Journal of Pharmaceutical Sciences 49 (1), 27-32, 2013 | 54 | 2013 |
| Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition T De Bruyn, W Sempels, J Snoeys, N Holmstock, S Chatterjee, B Stieger, ... Journal of pharmaceutical sciences 103 (6), 1872-1881, 2014 | 50 | 2014 |
| Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro–in vivo scaling of hepatic uptake clearance T De Bruyn, A Ufuk, C Cantrill, RE Kosa, Y Bi, M Niosi, S Modi, ... Drug Metabolism and Disposition 46 (7), 989-1000, 2018 | 47 | 2018 |
| Comparing mechanistic and preclinical predictions of volume of distribution on a large set of drugs R Chan, T De Bruyn, M Wright, F Broccatelli Pharmaceutical research 35, 1-11, 2018 | 39 | 2018 |
| Clearance prediction of HIV protease inhibitors in man: role of hepatic uptake T De Bruyn, B Stieger, PF Augustijns, PP Annaert Journal of pharmaceutical sciences 105 (2), 854-863, 2016 | 23 | 2016 |
| Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2 P Oranje, R Gouka, L Burggraaff, M Vermeer, C Chalet, G Duchateau, ... Pharmacology Research & Perspectives 7 (4), e00504, 2019 | 22 | 2019 |
| Verapamil hepatic clearance in four preclinical rat models: towards activity‐based scaling J Nicolaï, T De Bruyn, PP Van Veldhoven, J Keemink, P Augustijns, ... Biopharmaceutics & drug disposition 36 (7), 462-480, 2015 | 15 | 2015 |
| Simultaneous assessment in vitro of transporter and metabolic processes in hepatic drug clearance: use of a media loss approach J Harrison, T De Bruyn, AS Darwich, JB Houston Drug Metabolism and Disposition 46 (4), 405-414, 2018 | 13 | 2018 |
| Stability of therapeutic albumin solutions used for molecular adsorbent recirculating system‐based liver dialysis T De Bruyn, B Meijers, P Evenepoel, R Laub, L Willems, P Augustijns, ... Artificial Organs 36 (1), 29-41, 2012 | 11 | 2012 |
| Transport-metabolism interplay of atazanavir in rat hepatocytes J Nicolaï, T De Bruyn, L Thevelin, P Augustijns, P Annaert Drug Metabolism and Disposition 44 (3), 389-397, 2016 | 10 | 2016 |
| Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds J Mao, F Ma, J Yu, TD Bruyn, M Ning, C Bowman, Y Chen Biopharmaceutics & Drug Disposition 44 (4), 315-334, 2023 | 9 | 2023 |
| Drug-induced cholestasis assay in primary hepatocytes P Van Brantegem, S Chatterjee, T De Bruyn, P Annaert, N Deferm MethodsX 7, 101080, 2020 | 8 | 2020 |
| Hepatic clearance prediction of nine human immunodeficiency virus protease inhibitors in rat T De Bruyn, PF Augustijns, PP Annaert Journal of pharmaceutical sciences 105 (2), 846-853, 2016 | 8 | 2016 |
Prof. Gerard JP van WestenPI Computational Drug Discovery (Professor AI & Med Chem, Leiden University)在 gjpvanwesten.nl 的电子邮件经过验证
Prof. Gerard JP van WestenPI Computational Drug Discovery (Professor AI & Med Chem, Leiden University)在 gjpvanwesten.nl 的电子邮件经过验证